Literature DB >> 8262590

Bone marrow transplantation.

T S Vats1.   

Abstract

Bone marrow transplantations have a definite role in treatment of leukemias and lymphomas. In acute myeloid leukemia and CML an allogeneic transplant using an HLA identical donor certainly provides a far superior survival than chemotherapy. Patients with Ph' chromosome need to be transplanted in first remission if a suitable donor is available. In recurrent lymphomas the best results are achieved if the patient is transplanted in complete remission. Transplantation done using minor mismatched family donors or unrelated donors are still considered experimental and more data is needed before final recommendations can be made. Availability of supportive services is an absolute must prior to establishing transplant program. Selection of patients for transplantation should be done after carefully reviewing the indications and discussing with the family the emotional, financial and physical burden of the procedure. For selected indications in leukemias and lymphomas, BMT may be the only viable treatment option and therefore must be considered.

Entities:  

Mesh:

Year:  1993        PMID: 8262590     DOI: 10.1007/bf02751432

Source DB:  PubMed          Journal:  Indian J Pediatr        ISSN: 0019-5456            Impact factor:   1.967


  36 in total

1.  Marrow transplantation for acute nonlymphoblastic leukemia in first remission.

Authors:  E D Thomas; C D Buckner; R A Clift; A Fefer; F L Johnson; P E Neiman; G E Sale; J E Sanders; J W Singer; H Shulman; R Storb; P L Weiden
Journal:  N Engl J Med       Date:  1979-09-13       Impact factor: 91.245

2.  Treatment of malignant lymphoma with high dose of chemo or chemoradiotherapy and bone marrow transplantation.

Authors:  B Mascret; D Maraninchi; J A Gastaut; N Tubiana; G Sebahoun; N Horschowski; D Sainty; J Camerlo; C Lejeune; G Novakovitch
Journal:  Eur J Cancer Clin Oncol       Date:  1986-04

3.  Allogeneic marrow transplantation for acute nonlymphoblastic leukemia after first relapse.

Authors:  F R Appelbaum; R A Clift; C D Buckner; P Stewart; R Storb; K M Sullivan; E D Thomas
Journal:  Blood       Date:  1983-05       Impact factor: 22.113

4.  Prolonged complete remission following high dose chemotherapy of Burkitt's lymphoma in relapse.

Authors:  F R Appelbaum; A B Deisseroth; R G Graw; G P Herzig; A S Levine; I T Magrath; P A Pizzo; D G Poplack; J L Ziegler
Journal:  Cancer       Date:  1978-03       Impact factor: 6.860

5.  Autologous bone marrow transplantation for patients with acute lymphoblastic leukemia in second or subsequent remission: results of bone marrow treated with monoclonal antibodies BA-1, BA-2, and BA-3 plus complement.

Authors:  N Ramsay; T LeBien; M Nesbit; P McGlave; D Weisdorf; P Kenyon; D Hurd; A Goldman; T Kim; J Kersey
Journal:  Blood       Date:  1985-09       Impact factor: 22.113

6.  Autologous bone marrow transplantation in patients with acute nonlymphocytic leukemia, using ex vivo marrow treatment with 4-hydroperoxycyclophosphamide.

Authors:  A M Yeager; H Kaizer; G W Santos; R Saral; O M Colvin; R K Stuart; H G Braine; P J Burke; R F Ambinder; W H Burns
Journal:  N Engl J Med       Date:  1986-07-17       Impact factor: 91.245

Review 7.  Karnofsky Memorial Lecture. Marrow transplantation for malignant diseases.

Authors:  E D Thomas
Journal:  J Clin Oncol       Date:  1983-09       Impact factor: 44.544

8.  Bone marrow transplantation for non-Hodgkin's lymphoma in children and young adults. A pilot study.

Authors:  M O'Leary; N K Ramsay; M E Nesbit; D Hurd; W G Woods; W Krivit; T H Kim; P McGlave; J Kersey
Journal:  Am J Med       Date:  1983-03       Impact factor: 4.965

Review 9.  Bone marrow transplantation in the management of childhood cancer.

Authors:  J J Quinn
Journal:  Pediatr Clin North Am       Date:  1985-06       Impact factor: 3.278

10.  A comparison of marrow transplantation with chemotherapy for children with acute lymphoblastic leukemia in second or subsequent remission.

Authors:  F L Johnson; E D Thomas; B S Clark; R L Chard; J R Hartmann; R Storb
Journal:  N Engl J Med       Date:  1981-10-08       Impact factor: 91.245

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.